Skip to main content
. 2020 Apr 14;15(5):633–642. doi: 10.2215/CJN.15951219

Table 3.

Urine biomarkers of kidney injury after administration of 90 mg tin protoporphyrin

Analyte per Participant Subgroup Baseline Day 1 Day 2 Day 3 Day 4 P Value
NAG (mU/mg Cr) 2.0±1.5 2.83±1.167.5 3.16±1.16 2.51±0.64 2.66±0.8 0.35
 HVs
 CKD3 4.4±3.52 5.66±3.44 8.2±3.44 6.5±1.7 5.9±2.1 0.11
 CKD4 9.0±4.7 12.5±11.34 10.6±7.5 10.5±5.6 6.2±3.4 0.21
NGAL (ng/mg Cr)
 HVs 14.3±18.2 21.1±28.7 14.8±13.1 14.0±8.7 10.2±5.6 0.9
 CKD3 71.2±64.1 46.5±35.3 35.8±23.2 49.8±39.7 42.6±51.7 0.41
 CKD4 46.5±58.7 58.0±79.1 64.8±91.0 47.3±60.2 48.0±49.5 0.49
Cystatin C (ng/mg Cr)
 HVs 30.0±19.5 32.1±15.1 34.8±7.2 39.6±9.4 40.4±9.3 0.49
 CKD3 31.0±7.7 26.8±12.9 32.2±9.8 34.0±9.4 33.2±33.2 0.35
 CKD4 298±438 332±519 638±965 186±213 207±238 0.47
KIM-1 (ng/mg Cr)
 HVs 0.97±0.5 0.7±0.5 0.8±0.7 0.7±0.4 0.6±0.4 0.5
 CKD3 0.6±0.2 0.8±0.2 1.5±0.6 1.4±0.6 0.9±0.2 0.08
 CKD4 0.8±0.5 0.8±1.0 1.2±1.0 1.2±1.0 1.0±0.8 0.11

The urinary biomarker values, as factored by urine creatinine. The eGFRs were assessed at baseline and days 1–4 post–tin protoporphyrin injection. No significant changes over time were observed for any of the analytes (see P values). All values=means±1 SD. The P values are given for changes over time. NAG, N-acetyl glucosaminidase; Cr, creatinine; HVs, healthy volunteers; CKD3, CKD stage 3 (eGFR of 30–59 ml/min per 1.73 m2); CKD4, CKD stage 4 (eGFR of 15–29 ml/min per 1.73 m2); NGAL, neutrophil gelatinase-associated lipocalin; KIM-1, kidney injury molecule 1.